Key points are not available for this paper at this time.
Donepezil may enhance glucose utilization in failing rat hearts; leaves open translation to human CHF therapy.
Background: Donepezil, an acetylcholinesterase inhibitor, is reported to prevent cardiac pumping dysfunction in rats with chronic heart failure (CHF). Because energy substrate switching is a potential therapeutic target for the pharmacological treatment of CHF, we investigated the effect of donepezil on cardiac energy metabolism.
No takes yet. Share an insight, caveat, or question.
Mikihiko Arikawa (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: